Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果